Cheetham Group

Next generation RNA vaccines and therapeutics

The Cheetham Group’s research program focuses on next generation RNA vaccines and therapeutics. mRNA technologies are a new paradigm for therapy and vaccinology; however, their full potential is yet to be realised. First-generation mRNA vaccines have simple designs that do not yet take advantage of the latest advances in RNA sciences. We use approaches including modified nucleotides, RNA structural elements, high-throughput screening, circularisation, and transcriptomics to improve the properties of therapeutic RNAs.

The mRNAs that the Cheetham Group designs are used in diverse applications including vaccines, cellular reprogramming, and onco-immunology to treat intractable diseases.


Group leader


CHEETHAM, S. W., & Brand, A. H. (2018). RNA-DamID reveals cell-type-specific binding of roX RNAs at chromatin-entry sites. Nature Structural and Molecular Biology 25 (1): 109–14

Troskie, R. L., Jafrani, Y., Mercer, T. R., Ewing A. D. #, Faulkner G. J. #, & CHEETHAM, S. W. # (2021). Long-read cDNA sequencing identifies functional pseudogenes in the human transcriptome. Genome Biology 146 (21). #correspondence

van den Ameele, J.*, Krautz, R.*, CHEETHAM, S. W.*, et al., 'Reduced chromatin accessibility correlates with resistance to Notch activation', Nature Communications 2210 (13). *co-first authors

Ewing, A. D#., et al., CHEETHAM, S. W.#, & Faulkner, G. J#. (2020). Nanopore sequencing enables comprehensive transposable element epigenomic profiling. Molecular Cell 80 (5): 915–28.e5. #correspondence

CHEETHAM, S. W.*, Gruhn, W. H.*, van den Ameele, J.*, Krautz, R., et al.*, (2018). Targeted DamID reveals differential binding of mammalian pluripotency factors. Development. 145 (20) *co-first authors

Full list of publications available of espace